Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting dihydrofolate to tetrahydrofolate. This reduces the supply of reduced folate needed for synthesis of thymidine and purines, thereby limiting DNA replication and cell division, especially in rapidly proliferating cancer cells and activated immune cells.

The dose of Methotrexat Ebewe is individualized and set by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and concurrent therapies. No standard dosing can be provided here; the prescriber will calculate the appropriate regimen for each patient.

Methotrexat Ebewe is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause fetal malformations and loss. It is also not recommended while breastfeeding, as it may be excreted in milk and harm the infant. Effective contraception is required for women of child‑bearing potential.

To order Methotrexat Ebewe, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Methotrexat Ebewe (methotrexate) is a folate antagonist, whereas other antimetabolites such as azathioprine or 6‑mercaptopurine act on purine synthesis via different pathways. Methotrexate generally offers a broader range of approved indications, including certain cancers, and is often preferred for rheumatoid arthritis and psoriasis due to extensive clinical experience.

Methotrexat Ebewe should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and prevent moisture exposure. Follow local pharmacy or hospital handling guidelines for injectable medicines.

Methotrexat Ebewe is supplied for intravenous use. It is administered by a healthcare professional as an infusion or injection, typically over a short period, according to the prescriber's instructions. The exact rate, dilution, and frequency depend on the indication and individual patient factors.

Serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression leading to pancytopenia, and renal failure. Patients should be monitored regularly for signs of hepatic dysfunction, respiratory symptoms, abnormal blood counts and kidney function. Prompt medical attention is required if any of these serious adverse events occur.

Methotrexat Ebewe should be avoided in pregnant or breastfeeding women, patients with severe hepatic or renal impairment, those with active infections, and individuals with known hypersensitivity to methotrexate or any excipients in the formulation. Clinicians must also assess contraindications related to concurrent medications that may increase toxicity.